Interview with Tabitha Matthews, MSN, APRN-NP, AGACNP-BC, AOCNP: Risk Evaluation and Mitigation Strategies (REMS) Removal and Impact on Care Delivery

Interview with Joanne Wilson, APRN-NP, DNP: CAR T-Cell Therapy for Solid Tumors

Interview with Joanne Wilson, APRN-NP, DNP: TIL Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Liza Rodriguez, DNP, E-MBA, APRN, AOCNP
APP Manager Hematology/Blood and Marrow Transplant Program
APP Council Chair
Division of Hematologic Malignancies and Cellular Therapeutics
The University of Kansas Cancer Center

CAR T-Cell Therapy Resource Center

Interview with Tabitha Matthews, MSN, APRN-NP, AGACNP-BC, AOCNP: Risk Evaluation and Mitigation Strategies (REMS) Removal and Impact on Care Delivery

Prophylactic Corticosteroid Use in Patients Receiving Axicabtagene Ciloleucel for Large B-Cell Lymphoma

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

SITC Clinical Practice Guideline on Immune Effector Cell-related Adverse Events

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

American Cancer Society: CAR T-Cell Therapy and its Side Effects

Diagnostics (Basel)

CAR-T cell therapy in ovarian cancer: Where are we now?

EBioMedicine

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

Blood

Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy

Future Oncology

Establishing a successful outpatient CAR T-cell program with cilta-cel: Real-world experience from an expert roundtable

Seminars in Arthritis and Rheumatism

Advancing autoimmune rheumatic disease treatment: CAR T-cell therapies—evidence, safety, and future directions

Nature Reviews Immunology

In vivo CAR engineering for immunotherapy

Journal for ImmunoTherapy of Cancer

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR T-cell therapy in solid tumors

U.S. Food and Drug Administration

FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies

Stem Cells Translational Medicine

Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy

Journal for ImmunoTherapy of Cancer

Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

Fast Facts #12: BCMA Targets